Market Overview

Benzinga's Top Downgrades

Related NVS
Eli Lilly Beats on Q2 Earnings & Revs, Maintains View
5 New Medical Technologies For Diabetics
Bayer Buys Merck Consumer Care Unit (Fox Business)
Related ZIOP
ZIOPHARM Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update
Mid-Morning Market Update: Markets Gain On Jobs Data; VeriFone Earnings Beat Estimates

Analysts at Deutsche Bank downgraded Novartis AG (NYSE: NVS) from “buy” to “hold.” Novartis' shares closed at $63.20 yesterday. Novartis' trailing-twelve-month ROA is 6.24%.

Analysts at Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from “buy” to “hold.” ZIOPHARM's shares closed at $4.44 yesterday. ZIOPHARM's trailing-twelve-month ROE is -110.59%.

Analysts at Wells Fargo downgraded Stifel Financial (NYSE: SF) from “market perform” to “underperform.” Stifel Financial's shares closed at $31.45 yesterday. Stifel Financial's PEG ratio is 0.81.

Brean Capital downgraded IDEX (NYSE: IEX) from “buy” to “hold.” IDEX's shares closed at $45.98 yesterday. IDEX's trailing-twelve-month profit margin is 10.50%.

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Most Popular

Related Articles (IEX + NVS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters